›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:TruSight Tumor 170 Assay
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
IlluminaType:
Laboratory Developed Test
Related tests:
TruSight Tumor 170, a next-generation sequencing assay designed to cover 170 genes associated with common solid tumors, is an enrichment-based targeted panel that simultaneously analyzes DNA and RNA, covering a wide range of genes and variant types.
Cancer:
Solid Tumor
Gene:
AKT1 (V-akt murine thymoma viral oncogene homolog 1), AKT2 (V-akt murine thymoma viral oncogene homolog 2), AKT3 (V-akt murine thymoma viral oncogene homolog 3), ATM (ATM serine/threonine kinase), BAP1 (BRCA1 Associated Protein 1), BARD1 (BRCA1 Associated RING Domain 1)
See More ...
AKT1 (V-akt murine thymoma viral oncogene homolog 1), AKT2 (V-akt murine thymoma viral oncogene homolog 2), AKT3 (V-akt murine thymoma viral oncogene homolog 3), ATM (ATM serine/threonine kinase), BAP1 (BRCA1 Associated Protein 1), BARD1 (BRCA1 Associated RING Domain 1), BCL2 (B-cell CLL/lymphoma 2), BCL6 (B-cell CLL/lymphoma 6), BRAF (B-raf proto-oncogene), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1), CARD11 (Caspase Recruitment Domain Family Member 11), CCND1 (Cyclin D1), CCND2 (Cyclin D2), CCNE1 (Cyclin E1), CDH1 (Cadherin 1), CDK4 (Cyclin-dependent kinase 4), CDK6 (Cyclin-dependent kinase 6), CEBPA (CCAAT Enhancer Binding Protein Alpha), CHEK1 (Checkpoint kinase 1), CHEK2 (Checkpoint kinase 2), CREBBP (CREB binding protein), EGFR (Epidermal growth factor receptor), ER (Estrogen receptor), ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3), ERBB4 (erb-b2 receptor tyrosine kinase 4), EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit), FANCI (FA Complementation Group I), FANCL (FA Complementation Group L), FGFR1 (Fibroblast growth factor receptor 1), FGFR2 (Fibroblast growth factor receptor 2), FGFR3 (Fibroblast growth factor receptor 3), FGFR4 (Fibroblast growth factor receptor 4), FLT1 (Fms-related tyrosine kinase 1), FLT3 (Fms-related tyrosine kinase 3), GNAQ (G Protein Subunit Alpha Q), GNAS (GNAS Complex Locus), HER-2 (Human epidermal growth factor receptor 2), IDH1 (Isocitrate dehydrogenase (NADP(+)) 1), IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2), JAK2 (Janus kinase 2), JAK3 (Janus Kinase 3), MAP2K1 (Mitogen-activated protein kinase kinase 1), MAP2K2 (Mitogen-activated protein kinase kinase 2), MET (MET proto-oncogene, receptor tyrosine kinase), MLH1 (MutL homolog 1), MUTYH (MutY homolog), MYC (V-myc avian myelocytomatosis viral oncogene homolog), MYCN (MYCN Proto-Oncogene BHLH Transcription Factor), NOTCH1 (Notch 1), NOTCH2 (Notch 2), NOTCH3 (Notch Receptor 3), NPM1 (Nucleophosmin 1), PDGFRA (Platelet Derived Growth Factor Receptor Alpha), PDGFRB (Platelet Derived Growth Factor Receptor Beta), PTCH1 (Patched 1), PTEN (Phosphatase and tensin homolog), RET (Ret Proto-Oncogene), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS), SMO (Smoothened Frizzled Class Receptor), TP53 (Tumor protein P53), mTOR (Mechanistic target of rapamycin kinase)
Method:
Next-Generation Sequencing (NGS)
